<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1508">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789512</url>
  </required_header>
  <id_info>
    <org_study_id>2021-189</org_study_id>
    <nct_id>NCT04789512</nct_id>
  </id_info>
  <brief_title>Respiratory Muscle Strength in Volleyball Players Suffered From COVID-19</brief_title>
  <official_title>Evaluation of Respiratory Muscle Strength and Pulmonary Functions in Volleyball Players Suffering From Covid-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gazi University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gazi University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In literature, there is no data evaluating respiratory functions in volleyball players during&#xD;
      Covid-19 pandemic. The aim of this study is to evaluate and compared pulmonary functions,&#xD;
      respiratory muscle strength, body compositions and performance situations perceptions in&#xD;
      female volleyball players with Covid-19 and non-Covid-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Actual">March 29, 2021</completion_date>
  <primary_completion_date type="Actual">March 26, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory muscle strength</measure>
    <time_frame>10 minute</time_frame>
    <description>Maximal inspiratory and expiratory muscle strength will be evaluated using mouth pressure device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>5 minute</time_frame>
    <description>Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. FEV1 will be evaluated. The percentage of predicted value &lt;70% will be expressed as abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC</measure>
    <time_frame>5 minute</time_frame>
    <description>Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. FVC will be evaluated. The percentage of predicted value &lt;70% will be expressed as abnormal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC</measure>
    <time_frame>5 minute</time_frame>
    <description>Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. FEV1/FVC will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF</measure>
    <time_frame>5 minute</time_frame>
    <description>Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. PEF will be evaluated. The percentage of predicted value &lt;70% will be expressed as abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEF2575</measure>
    <time_frame>5 minute</time_frame>
    <description>Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. FEF2575 will be evaluated. The percentage of predicted value &lt;50% will be expressed as abnormal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass</measure>
    <time_frame>2 minute</time_frame>
    <description>Fat mass will be evaluated using TANITA bioelectrical impedance analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass percent</measure>
    <time_frame>2 minute</time_frame>
    <description>Fat mass percent will be evaluated using TANITA bioelectrical impedance analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat-free mass</measure>
    <time_frame>2 minute</time_frame>
    <description>Fat-free mass will be evaluated using TANITA bioelectrical impedance analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>2 minute</time_frame>
    <description>Body mass index will be evaluated using TANITA bioelectrical impedance analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predicted muscle mass</measure>
    <time_frame>2 minute</time_frame>
    <description>Predicted muscle mass will be evaluated using TANITA bioelectrical impedance analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity perceptions</measure>
    <time_frame>1 minute</time_frame>
    <description>Symptom severity perceptions will be evaluated Numeric Rating Scale.The severity of symptoms perceptions related to Covid are scored 0-10 point. Higher scores indicate higher severity of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance situations perceptions</measure>
    <time_frame>1 minute</time_frame>
    <description>Performance situations perceptions will be evaluated Numeric Rating Scale. Performance situations perceptions of all players are also scored 0-10 point. Higher scores indicate greater performance.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Covid-19 players</arm_group_label>
    <description>Female volleyball players with Covid-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-Covid-19 players</arm_group_label>
    <description>Female volleyball players with non Covid-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Respiratory functions</intervention_name>
    <description>Respiratory muscle strength, pulmonary functions and body composition were evaluated in volleyball players</description>
    <arm_group_label>Covid-19 players</arm_group_label>
    <arm_group_label>non-Covid-19 players</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female volleyball players&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  having passed at least 30 days after the Polymerase Chain Reaction (PCR) test turned&#xD;
             negative&#xD;
&#xD;
          -  willing to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  having a history of chronic lung disease&#xD;
&#xD;
          -  unwilling to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gazi University</name>
      <address>
        <city>Ankara</city>
        <state>Çankaya</state>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 6, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gazi University</investigator_affiliation>
    <investigator_full_name>Zeliha ÇELİK</investigator_full_name>
    <investigator_title>Research assistant</investigator_title>
  </responsible_party>
  <keyword>respiratory muscles</keyword>
  <keyword>pulmonary functions</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

